Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN5 | P54829 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CFTR | P13569 | 2/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.34 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25451269 | 0.88 | POLB (0.43) | PTPN5ALDH1A1KDM4EPKMHPGD | |
| SCHEMBL13871750 | 0.86 | PTPN5 (0.47) | PTPN5ALDH1A1KDM4EPKMHPGD | |
| SCHEMBL3190814 | 0.84 | CES2 (0.40) | IKBKBCES2CACNA1HCACNA1GCACNA1C | |
| SCHEMBL21865966 | 0.82 | PTPN5 (0.44) | PTPN5ALDH1A1KDM4EPKMHPGD | |
| SCHEMBL15761590 | 0.80 | SMN1; SMN2 (0.41) | ALDH1A1KDM4EHPGDHSD17B10CFTR | |
| Ammonia Solution, Strong SCHEMBL27470283 | 0.80 | PTPN5 (0.42) | PTPN5ALDH1A1KDM4EPKMHPGD | |
| SCHEMBL24118132 | 0.80 | TSHR (0.45) | ALDH1A1KDM4EHPGDHSD17B10CFTR | |
| SCHEMBL13550134 | 0.79 | RAPGEF4 (0.39) | CES2CACNA1HCACNA1GARCACNA1C | |
| SCHEMBL205002 | 0.77 | ALDH1A1 (0.50) | PTPN5ALDH1A1KDM4EPKMHPGD | |
| SCHEMBL27764178 | 0.77 | PTPN5 (0.44) | PTPN5ALDH1A1KDM4EPKMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713293-B2 | Substituted biaryl sulfonamides and the use thereof | NOVOMEDIX, LLC (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220002240-A1 | SUBSTITUTED BIARYL SULFONAMIDES AND THE USE THEREOF | NOVOMEDIX LLC (US) | 2022-01-06 | — | — | US | disclosed |
| US-20200062700-A1 | SUBSTITUTED BIARYL SULFONAMIDES AND THE USE THEREOF | NOVOMEDIX LLC (US) | 2020-02-27 | — | — | US | disclosed |
| EP-3514163-A1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | Samsung Electronics Co., Ltd. (KR) | 2019-07-24 | — | — | EP | disclosed |
| US-20180327353-A1 | SUBSTITUTED BIARYL SULFONAMIDES AND THE USE THEREOF | NOVOMEDIX LLC (US) | 2018-11-15 | — | — | US | disclosed |
| US-10040757-B2 | Substituted biaryl sulfonamides and the use thereof | NOVOMEDIX, LLC (US) | 2018-08-07 | — | — | US | disclosed |
| EP-2925718-B1 | SUBSTITUTED BIARYL SULFONAMIDES AND THE USE THEREOF | NOVOMEDIX LLC (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-2925718-B1 | SUBSTITUTED BIARYL SULFONAMIDES AND THE USE THEREOF | NOVOMEDIX LLC (US) | 2018-08-01 | — | — | EP | disclosed |
| US-20170158627-A1 | SUBSTITUTED BIARYL SULFONAMIDES AND THE USE THEREOF | NOVOMEDIX, LLC | 2017-06-08 | — | — | US | disclosed |
| US-9604924-B2 | Substituted biaryl sulfonamides and the use thereof | NOVOMEDIX, LLC (US) | 2017-03-28 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20060122243-A1 | Antiallergic | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| US-20060111409-A1 | Medicament for treatment of diabetes | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-25 | — | — | US | disclosed |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-11 | — | — | US | disclosed |
| WO-2006013210-A2 | 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | NEUROSEARCH A/S (DK) | 2006-02-09 | — | — | WO | disclosed |
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327353-A1 | SUBSTITUTED BIARYL SULFONAMIDES AND THE USE THEREOF | EIF2AK2, TP53, KRAS | PTPN5 3286/4885ALDH1A1 2107/4885KDM4E 568/4885 |
| US-11713293-B2 | Substituted biaryl sulfonamides and the use thereof | EIF2AK2, TP53, KRAS | PTPN5 3286/4885ALDH1A1 2107/4885KDM4E 568/4885 |
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | MAP3K1, MAP3K7, MAP3K8 | PTPN5 1035/4885ALDH1A1 3396/4885KDM4E 1319/4885 |
| US-20220002240-A1 | SUBSTITUTED BIARYL SULFONAMIDES AND THE USE THEREOF | EIF2AK2, TP53, KRAS | PTPN5 3191/4885ALDH1A1 2041/4885KDM4E 603/4885 |
| US-20170158627-A1 | SUBSTITUTED BIARYL SULFONAMIDES AND THE USE THEREOF | EIF2AK2, TP53, KRAS | PTPN5 3286/4885ALDH1A1 2107/4885KDM4E 568/4885 |
| US-20060111409-A1 | Medicament for treatment of diabetes | XDH, SLC5A1, SLC5A2 | PTPN5 1929/4885ALDH1A1 469/4885KDM4E 3430/4885 |
| US-20200062700-A1 | SUBSTITUTED BIARYL SULFONAMIDES AND THE USE THEREOF | EIF2AK2, TP53, KRAS | PTPN5 3286/4885ALDH1A1 2107/4885KDM4E 568/4885 |
| US-20060122243-A1 | Antiallergic | EPX, NAT1, HNMT | PTPN5 3523/4885ALDH1A1 296/4885KDM4E 1633/4885 |
| US-10040757-B2 | Substituted biaryl sulfonamides and the use thereof | EIF2AK2, TP53, KRAS | PTPN5 3286/4885ALDH1A1 2107/4885KDM4E 568/4885 |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | NFATC1, AP1G1, ATF1 | PTPN5 564/4885ALDH1A1 1959/4885KDM4E 1369/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | PTPN5 3401/4885ALDH1A1 362/4885KDM4E 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.